Trials / Completed
CompletedNCT01589159
A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Tao OUYANG · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | Drug:capecitabine 700mg/m2, twice daily on days 1-14. |
| DRUG | Etoposide | Etoposide 30mg/m2, once daily on days 1-7. |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-07-01
- Completion
- 2016-12-01
- First posted
- 2012-05-01
- Last updated
- 2017-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01589159. Inclusion in this directory is not an endorsement.